Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Abstract: This invention relates to a cellulase treatment of cellulosic fabric to achieve biopolishing effects, reducing dust or lint and reducing pilling during at least one laundry cycle in said fabric comprising treating said fabric with cellulase after the scouring step and before the bleaching step.

Abstract: A method is presented for inactivating undesired acid labile proteases which are expressed into the culture medium simultaneously with desired enzymes by Aspergillus species when Aspergillus species is used as the host for recombinantly producing enzymes. The method involves incubating culture medium which contains a mixture of the desired recombinantly produced enzyme and the undesired acid labile protease which have been expressed therein at pH values below 4.5 and at temperatures from 2.degree. C. to 75.degree. C. for at least 20 seconds.

Abstract: The present invention provides methods for reducing the water content of an oil or fat sample, which are carried out by treating the sample with a lipolytic enzyme. Substances that are insoluble in oil or fat, which are precipitated as a result of the water-removing method, may then be removed to purify the oil or fat. The purified oil or fat may also be hydrolyzed to produce hydrolysates of oil or fat.

Abstract: The present invention relates to a process for producing a therapeutic powder formulation, comprising (a) providing an acidic aqueous solution comprising an insulin or analoguc or derivative thereof and an enhancer; (b) adjusting the pH to a pH in the range of 4.5 to 7.4; (c) precipitating a product comprising the insulin or analogue or derivative thereof and the enhancer, wherein the precipitation is performed essentially without evaporation of the solution; and (d) removing the water.

Abstract: The present invention relates to a method of constructing a variant of a parent Termamyl-like .alpha.-amylase, which variant has .alpha.-amylase activity and at least one altered property as compared to the parent .alpha.-amylase, comprising i) analyzing the structure of the parent Termamyl-like .alpha.-amylase to identify at least one amino acid residue or at least one structural part of the Termamyl-like .alpha.-amylase structure, which amino acid residue or structural part is believed to be of relevance for altering the property of the parent Termamyl-like .alpha.-amylase (as evaluated on the basis of structural or functional considerations), ii) constructing a Termamyl-like .alpha.-amylase variant, which as compared to the parent Termamyl-like .alpha.-amylase, has been modified in the amino acid residue or structural part identified in i) so as to alter the property, and iii) testing the resulting Termamyl-like .alpha.-amylase variant for the property in question.

Abstract: A pen shaped syringe with automatic needle insertion has an injection system integrally displaceable in a housing and comprising a basic part carrying a medicine reservoir with a hypodermic needle at its distal end, and a dosing mechanism with a carrier engaging a cogged piston rod, the carrier being coupled to a dose spindle in a rotatable but not displaceable way. The dose spindle is provided with a thread engaging a thread in a sequence part having protrusions engaging slots in the basic part to allow a limited axial movement of the parts in relation to each other, the extent of the movement being defined by the rotational position of the dose spindle. A spring is compressed between the basic part and the housing when the basic part is moved in the proximal direction by exerting a cocking force on the sequence part which part after having performed the set limited axial movement in relation to the basic part carries this basic part against the force of the spring.

Abstract: An insulin injection system comprises a pen shaped syringe with a cartridge containing insulin, and an injection needle. The needle is a G30 needle and the insulin is a type which may freely flow through a G 30 needle. When the insulin is the type comprising suspended crystals the maximal dimension of any crystal is 15 .mu.m.

Abstract: In a syringe dosing mechanism a threaded spindle (1) and a nut (3) cooperates so that relative rotation thereof moves the nut (3) along the spindle (1). The nut (3) has two intersecting bores (12, 15). The first bore (15) has an inner thread (7) matching the outer thread (2) of the spindle (1) and the second bore (12) is smooth and fits slidingly over the spindle (1). The nut (3) is tiltable between a first and a second position. In the first position the threaded bore (15) is coaxial with the spindle (1) and in the second position the smooth bore (12) is coaxial with the spindle (1). The nut (3) is at a first side hinged to a piston rod (6)so that exertion of a force by the nut (3) on the piston rod (6) in a direction (10) by which an injection is performed will tilt said nut (3) into its first position.

Abstract: The present invention provides novel uses of compounds of general formula I: ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of atrophy of skin and/or mucous membranes.

Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.